We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
-7.74%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$884M
AUM Growth
-$174M
Cap. Flow
-$27.4M
Cap. Flow %
-3.1%
Top 10 Hldgs %
89.11%
Holding
24
New
–
Increased
1
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$4.22M

Top Sells

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$27.8M
2
AVIR icon
Atea Pharmaceuticals
AVIR
+$3.01M
3
PVLA
Palvella Therapeutics
PVLA
+$580K
4
EPIX
ESSA Pharma
EPIX
+$252K

Sector Composition

Rank Sector Weight
1 Healthcare 99.44%
2 Financials 0.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVB icon
1
Nuvation Bio
NUVB
$2.24B
$263M 29.73%
28,212,376
– –
REPL icon
2
Replimune Group
REPL
$814M
$192M 21.78%
5,008,245
– –
MORF
3
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$101M 11.48%
1,767,350
-505,128
-22% -$27.8M
KRON
4
DELISTED
Kronos Bio
KRON
$91.4M 10.35%
3,818,283
– –
IMA
5
ImageneBio Inc
IMA
$63.1M
$31.6M 3.57%
187,427
– –
GOSS icon
6
Gossamer Bio
GOSS
$66.5M
$27M 3.05%
3,320,608
– –
SPRB
7
Spruce Biosciences
SPRB
$119M
$24.2M 2.74%
28,814
– –
IMUX icon
8
Immunic
IMUX
$182M
$21.9M 2.48%
178,816
– –
PRTK
9
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$17.7M 2.01%
2,600,410
– –
ARQT icon
10
Arcutis Biotherapeutics
ARQT
$3.42B
$17M 1.93%
623,836
– –
SANA icon
11
Sana Biotechnology
SANA
$885M
$16.6M 1.88%
843,750
– –
AVIR icon
12
Atea Pharmaceuticals
AVIR
$379M
$16M 1.82%
746,868
-100,340
-12% -$3.01M
SYRS
13
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$12.4M 1.4%
227,483
+71,233
+46% +$4.22M
ALPN
14
DELISTED
Alpine Immune Sciences Inc
ALPN
$11.6M 1.31%
1,284,900
– –
EPIX
15
DELISTED
ESSA Pharma
EPIX
$9.38M 1.06%
328,196
-8,673
-3% -$252K
CMPI
16
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
$7.96M 0.9%
1,335,050
– –
OMEG
17
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$4.99M 0.56%
501,000
– –
CDTX
18
DELISTED
Cidara Therapeutics
CDTX
$4.05M 0.46%
100,262
– –
KYNB
19
Kyntra Bio
KYNB
$28.5M
$3.48M 0.39%
5,226
– –
OBSV
20
DELISTED
ObsEva SA Ordinary Shares
OBSV
$3.03M 0.34%
999,364
– –
TRVI icon
21
Trevi Therapeutics
TRVI
$2.49B
$2.84M 0.32%
1,263,408
– –
IMCR icon
22
Immunocore
IMCR
$1.78B
$2.01M 0.23%
51,535
– –
JNCE
23
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$1.87M 0.21%
275,513
– –
PVLA
24
Palvella Therapeutics
PVLA
$1.98B
– –
-2,822
Closed -$580K

Similar funds

HCCM
Hudson Canyon Capital Management New York $163M AUM 33.71% 1-Year Est. Return
PBO
Peoples Bank (Ohio) Marietta, Ohio $163M AUM 18.72% 1-Year Est. Return
PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return

Omega Fund Management's Q2 2021 Portfolio in Review

As of Q2 2021, Omega Fund Management held 24 positions worth $884M, down 16% from $1.06B the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Omega Fund Management withdrew a net $27.4M in Q2 2021, closing 1 position and reducing 3 holdings. Its most notable exit was Palvella Therapeutics, an estimated $580K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

Against the trend, Omega Fund Management added an estimated $4.22M to Syros Pharmaceuticals, Inc. Common Stock.

  • Omega Fund Management added most to Syros Pharmaceuticals, Inc. Common Stock in Q2 2021, an estimated $4.22M increase.
  • Omega Fund Management's biggest Q2 2021 reduction was Morphic Holding, Inc. Common Stock, cutting an estimated $27.8M.
  • Omega Fund Management fully exited Palvella Therapeutics in Q2 2021, selling an estimated $580K.
  • Omega Fund Management's ten largest holdings make up 89% of its $884M portfolio in Q2 2021.
  • Omega Fund Management opened 0 new positions and closed 1 in Q2 2021.
  • Omega Fund Management's portfolio value fell 16% quarter-over-quarter to $884M.

Based on Omega Fund Management's 13F filing for Q2 2021, filed 16 Aug 2021.